+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Benign Prostatic Hypertrophy Drugs Market by Product (5-alpha-reductase Inhibitors, Alpha Blockers, Phosphodiesterase-5 Inhibitors), Sales Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Forecast 2024-2030

  • PDF Icon

    Report

  • 187 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5977967
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Benign Prostatic Hypertrophy Drugs Market grew from USD 5.15 billion in 2023 to USD 5.50 billion in 2024. It is expected to continue growing at a CAGR of 6.97%, reaching USD 8.26 billion by 2030.

Key medications within this sector include alpha-blockers, 5-alpha reductase inhibitors, and various combination therapies tailored to differing severity levels and patient needs. Major growth drivers in this market arise from an aging global population coupled with advancements in healthcare that boost accessibility and diagnosis rates. Furthermore, persistent innovations in drug development aimed at enhancing treatment efficacy and safety propel the market forward. Expansion opportunities are particularly significant in emerging economies with developing healthcare infrastructures and the ongoing quest for drug formulations that offer fewer side effects. However, the market faces challenges such as rigorous regulatory processes, the adverse effects associated with existing treatments, and saturation in developed markets, which can hinder the profitability and introduction of new drugs. Innovations such as bioengineered medications that target the prostate more selectively, investments in the exploration of new therapeutic pathways, and integrated approaches combining lifestyle, diet, and holistic treatments with traditional medications are pivotal areas for future research and development.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a well-established market for BPH drugs due to a high awareness of the condition and a strong healthcare infrastructure. The U.S. holds significant business growth, driven by its large aging population and the prevalence of lifestyle-associated diseases contributing to BPH. The market for BPH drugs in Europe is robust for reasons similar to those in the Americas: high prevalence of BPH, advanced healthcare systems, and strong diagnostic capabilities. Following comprehensive healthcare policies and access, Northern and Western Europe mainly show higher market penetration rates for these drugs. In the Middle East and Africa, the market is growing but at a slower pace, influenced by varying levels of healthcare access and economic disparity across these regions. However, increased urbanization and healthcare improvements are gradually boosting the availability of treatments. The Asia-Pacific region presents a diverse pharmaceutical landscape due to differing economic statuses, healthcare development levels, and population dynamics. Countries such as Japan, Australia, and South Korea have a high demand for BPH medications, paralleling trends in the Americas and Europe with aging populations and advanced healthcare infrastructures. The overall APAC market is expected to grow significantly due to increasing healthcare investments and awareness of the condition.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Benign Prostatic Hypertrophy Drugs Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Increasing global prevalence of benign prostatic hypertrophy
  • Supportive regulatory policies enhancing market approval efficiency

Market Restraints

  • High cost of BPH drugs and availability of alternate treatments

Market Opportunities

  • Advancements and innovation in BPH drug development
  • Increased investment in R&D for novel drug delivery technologies

Market Challenges

  • Product recalls due to safety concerns

Market Segmentation Analysis

  • Product: Increasing R&D towards development next generation benign prostatic hypertrophy drug
  • Sales Channel: Rising business growth across online pharmacies

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Benign Prostatic Hypertrophy Drugs Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Benign Prostatic Hypertrophy Drugs Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Zydus Lifesciences Secures USFDA Approval for Novel Prostate Treatment Capsules

Zydus Lifesciences has gained key approval from the United States Food and Drug Administration (USFDA) for its innovative capsule formulation of Finasteride and Tadalafil, with a dosage of 5 mg/5 mg. These capsules, aimed at treating benign prostatic hyperplasia, are produced at the company's Ahmedabad SEZ II facility in India. This new approval boosts Zydus's portfolio to 392 FDA approvals, supported by more than 460 abbreviated new drug applications.

Strategic Acquisition of ENTADFI by Blue Water Vaccines Inc. for Enhancing Treatment Options for Benign Prostatic Hyperplasia

Blue Water Vaccines Inc. (BWV) has entered into an agreement with Veru Inc. to acquire ENTADFI, an FDA-approved medication formulated for the management of benign prostatic hyperplasia (BPH), a prevalent non-cancerous enlargement of the prostate gland affecting a significant male demographic over age 50. The treatment, notable for mitigating the sexual dysfunction often associated with similar therapies, involves a purchase of USD 100 million with initial payments of USD 20 million and potential additional payments of USD 80 million, dependent on future sales milestones.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Benign Prostatic Hypertrophy Drugs Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Benign Prostatic Hypertrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Advin Health Care, Alembic Ltd., Asahi Kasei Corporation, Astellas Pharma Inc., biolitec Holding GmbH & Co KG, Boston Scientific Corporation, C.H. Boehringer Sohn AG & Co. KG, Care Formulation Labs Pvt. ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Intas Pharmaceuticals Limited, Medifocus Inc., Merck & Co., Inc., Nymox Pharmaceutical Corporation, Onconetix, Inc., Pfizer Inc., Pharex Health Corporation, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UNILAB, Inc., Urologix, LLC, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Benign Prostatic Hypertrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product

  • 5-alpha-reductase Inhibitors

Alpha Blockers

  • Alfuzosin
  • Doxazosin
  • Tamsulosin
  • Terazosin
  • Phosphodiesterase-5 Inhibitors

Sales Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing global prevalence of benign prostatic hypertrophy
5.1.1.2. Supportive regulatory policies enhancing market approval efficiency
5.1.2. Restraints
5.1.2.1. High cost of BPH drugs and availability of alternate treatments
5.1.3. Opportunities
5.1.3.1. Advancements and innovation in BPH drug development
5.1.3.2. Increased investment in R&D for novel drug delivery technologies
5.1.4. Challenges
5.1.4.1. Product recalls due to safety concerns
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing R&D towards development next generation benign prostatic hypertrophy drug
5.2.2. Sales Channel: Rising business growth across online pharmacies
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Benign Prostatic Hypertrophy Drugs Market, by Product
6.1. Introduction
6.2. 5-alpha-reductase Inhibitors
6.3. Alpha Blockers
6.4. Phosphodiesterase-5 Inhibitors
7. Benign Prostatic Hypertrophy Drugs Market, by Sales Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies
7.5. Specialty Pharmacies
8. Americas Benign Prostatic Hypertrophy Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Benign Prostatic Hypertrophy Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Benign Prostatic Hypertrophy Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Zydus Lifesciences Secures USFDA Approval for Novel Prostate Treatment Capsules
11.3.2. Strategic Acquisition of ENTADFI by Blue Water Vaccines Inc. for Enhancing Treatment Options for Benign Prostatic Hyperplasia
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHOSPHODIESTERASE-5 INHIBITORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 39. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 40. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 41. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 42. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 45. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 46. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 47. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 48. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 51. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 52. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 53. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 54. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 55. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 56. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 57. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 58. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 59. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 60. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 61. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 62. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 63. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 64. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 65. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 66. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 71. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 72. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 73. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 74. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 80. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 82. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 85. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 86. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 87. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 88. AUSTRALIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 89. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 90. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 91. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 92. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 93. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 94. CHINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 95. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 96. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 97. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 98. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 99. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 100. INDIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 103. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 104. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 105. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 106. INDONESIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 107. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 108. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 109. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 110. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 111. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 112. JAPAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 115. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 116. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 117. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 118. MALAYSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 121. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 122. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 123. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 124. PHILIPPINES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 127. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 128. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 129. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 130. SINGAPORE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 133. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 134. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 135. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 136. SOUTH KOREA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 139. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 140. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 141. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 142. TAIWAN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 143. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 144. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 145. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 146. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 147. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 148. THAILAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 151. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 152. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 153. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. VIETNAM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 163. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 164. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 165. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 166. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 167. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 168. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 169. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 170. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 171. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 172. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 173. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 174. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 175. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 176. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 177. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 178. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 179. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 180. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 181. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 182. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 183. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 184. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 185. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 186. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 187. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 188. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 189. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 190. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 191. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 192. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 195. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 196. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 197. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 198. ISRAEL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 199. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 200. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 201. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 202. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 203. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 204. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 207. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 208. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 209. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 210. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 213. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 214. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 215. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 216. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 217. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 218. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 219. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 220. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 221. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 222. NORWAY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 223. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 224. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 225. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 226. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 227. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 228. POLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 229. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 230. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 231. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 232. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 233. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 234. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 237. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 238. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 239. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 240. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 244. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 246. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 250. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 252. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 253. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 254. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 255. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 256. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 257. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 258. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 261. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 262. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 263. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 264. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 267. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 268. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 269. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 270. SWITZERLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 271. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 272. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 273. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 274. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 275. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 276. TURKEY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 280. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2023 (USD MILLION)
TABLE 286. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2024-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 288. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 289. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 290. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • AbbVie Inc.
  • Advin Health Care
  • Alembic Ltd.
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • biolitec Holding GmbH & Co KG
  • Boston Scientific Corporation
  • C.H. Boehringer Sohn AG & Co. KG
  • Care Formulation Labs Pvt. ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Intas Pharmaceuticals Limited
  • Medifocus Inc.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corporation
  • Onconetix, Inc.
  • Pfizer Inc.
  • Pharex Health Corporation
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • UNILAB, Inc.
  • Urologix, LLC
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.5 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.26 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal

Related Topics

Related Reports

Drugs For Benign Prostatic hypertrophy Global Market Report 2024 - Product Image

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Global Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class (5-Alpha Reductase Inhibitor, Alpha-Blocker, Phosphodiesterase-5 Inhibitor), Therapy (Combination Drug Therapy, Mono Drug Therapy), End User - Forecast 2024-2030 - Product Image

Global Benign Prostatic Hyperplasia Treatment Market by Therapeutic Class (5-Alpha Reductase Inhibitor, Alpha-Blocker, Phosphodiesterase-5 Inhibitor), Therapy (Combination Drug Therapy, Mono Drug Therapy), End User - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report - Product Image

Benign Prostatic Hyperplasia (BPH) Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Benign prostatic hyperplasia - Pipeline Insight, 2024 - Product Image

Benign prostatic hyperplasia - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.